Ovid Therapeutics, Inc. (OVID)
2.80
-0.13
(-4.44%)
USD |
NASDAQ |
Aug 28, 16:00
2.85
+0.05
(+1.79%)
After-Hours: 07:43
Ovid Therapeutics Total Liabilities (Quarterly) : 22.08M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 22.08M |
| March 31, 2026 | 27.36M |
| December 31, 2025 | 20.27M |
| September 30, 2025 | 19.15M |
| June 30, 2025 | 21.64M |
| March 31, 2025 | 22.38M |
| December 31, 2024 | 23.94M |
| September 30, 2024 | 26.36M |
| June 30, 2024 | 29.19M |
| March 31, 2024 | 53.33M |
| December 31, 2023 | 56.23M |
| September 30, 2023 | 23.74M |
| June 30, 2023 | 25.53M |
| March 31, 2023 | 22.42M |
| December 31, 2022 | 22.99M |
| September 30, 2022 | 22.98M |
| June 30, 2022 | 25.18M |
| March 31, 2022 | 26.10M |
| December 31, 2021 | 14.80M |
| Date | Value |
|---|---|
| September 30, 2021 | 10.06M |
| June 30, 2021 | 11.29M |
| March 31, 2021 | 16.35M |
| December 31, 2020 | 32.29M |
| September 30, 2020 | 27.96M |
| June 30, 2020 | 14.87M |
| March 31, 2020 | 10.28M |
| December 31, 2019 | 10.82M |
| September 30, 2019 | 10.65M |
| June 30, 2019 | 9.470M |
| March 31, 2019 | 9.410M |
| December 31, 2018 | 8.844M |
| September 30, 2018 | 10.42M |
| June 30, 2018 | 7.496M |
| March 31, 2018 | 6.579M |
| December 31, 2017 | 6.021M |
| September 30, 2017 | 4.608M |
| June 30, 2017 | 7.065M |
| March 31, 2017 | 4.868M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 231.97M |
| Shareholders Equity (Quarterly) | 209.89M |
| Debt to Equity Ratio | 0.0606 |
| Current Ratio | 12.39 |
| Net Debt Paydown Yield | 0.07% |